logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: share
Load new posts () and activity
Like Reblog Comment
text 2019-03-23 07:46
Pompe Disease Therapeutic Market 2018: Global Industry Analysis, Growth, Trends and Forecast To 2026

Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of enzyme acid named alpha-glucosidase (GAA). This causes the glycogen to accumulate in different kinds of tissues, primarily into smooth muscles, skeletal muscles and cardiac muscle. It leads to muscle weakness, respiratory problems, and may also affects the liver and heart. Pompe disease is inherited as an autosomal recessive genetic trait. There are three major types of pompe disease, which differ in severity and appear at different age, these types are known as classic infantile-onset, which starts within a few months of birth, non-classic infantile-onset Pompe disease- usually appears by age 1, and late-onset type of Pompe disease that may shows the symptoms later in childhood, adolescence, or adulthood. Pompe disease therapeutic market can exhibit immense growth potential due to presence of limited number of manufacturers, which can significantly enhance and expand their business potential and scope in this market.

 

Key players operating in the pompe disease therapeutic market include Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, and Sangamo Therapeutics, Inc.

 

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1316

 

Increasing government initiatives is expected to augment growth of the pompe disease therapeutic market

Considering the public health problems, government is taking continuous initiatives in promoting and advancing the development of innovative products for the prevention and diagnosis or treatment of rare diseases or conditions such as Pompe disease. For instance, in 2015, Orphan Product Grants Program funded 18 new grant awards from 92 grant applications and provided funding and support to around 67 ongoing clinical study projects related to rare disease. Furthermore, initiatives from the governments of economies such as Sweden, the Netherlands, and South Korea that focus on approving guidelines for the reimbursement of individuals undergoing enzyme replacement therapy (ERT) are also expected to boost growth of the pompe disease therapeutic market in near future.

 

Increasing prevalence of pompe disease in many economies is expected to have a lucrative opportunities for pharmaceutical manufacturers to come with a tailored solution for diagnosis and treatment of disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated frequency occurrence of Pompe disease may vary among different ethnic groups and nationalities: in Holland: 1 in 40,000 (Adults: 1 in 57,000; Infantile: 1 in 138,000), Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and Caucasian: 1 in 100,000 suffer from pompe disease. Gene therapy and enzyme replacement therapy may be highly effective at reducing clinical manifestations of this rare disease. Currently, there are two commercialized products in enzyme replacement therapy, which are Myozyme for the treatment of infants and children with Pompe disease and Lumizyme for late-onset non-infantile Pompe disease. Furthermore, various pipeline products in phase 3 (NeoGAA GZ402666 (Sanofi), AT-982 (Audentes therapeutics)) and in phase 2 (BMN 701(Biomarin)) clinical trial are also expected to create a meteoric growth in this market during the forecast period. However, the high cost associated with the treatment and long duration of the treatment are the factors restraining growth of the pompe disease therapeutic market. For instance, according to a research paper published by Harvard School, in 2016, Lumizyme accounted for US$ 100,000 per year for children and US$ 300,000 per year for adult treatments.

 

Increasing investments in research and development by manufacturers is expected to propel the market growth

Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. This novel treatment paradigm consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P) to enhance uptake, co-administered with AT2221, a pharmacological chaperone.

 

Click To Read More On Pompe Disease Therapeutic Market

Like Reblog Comment
text 2019-03-22 12:56
Levodopa Market Upcoming Trends, Demand and Analysis Till 2026

Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson's disease (PD) at early stage of the disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine. Click To Read More On Levodopa Market


Levodopa Market Driver


Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.


Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.


Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.


Levodopa Market Restraint


Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.


Competitive Landscape


The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.


Levodopa Market – Regional Analysis


On the basis of region, the global levodopa market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.


North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2247


Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.


Furthermore, in November 2015, Impax Laboratories, Inc. received European Commission (EC) marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease in Europe region.


Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com


https://www.coherentmarketinsights.com/phase-xs/


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Like Reblog Comment
text 2019-03-22 11:42
Legionella Testing Market Size and Application Analysis by 2020

22 March 2019, The Global Legionella Testing Market is expected to grow at a considerable rate over the forecast period owing to the advancements and automation in the immunodiagnostic market such as the introduction of advanced ELISA antibodies for the prevention of legionnaires diseases in the market. The rapidly rising awareness about legionella based diseases and the increase in demand for advanced immunodiagnostic techniques is a direct consequence of rapidly increasing incidences of mild flu and pneumonia like diseases through legionella bacteria. Since legionella bacteria requires the presence of iron and cysteine to grow, it is traditionally detected by culture on buffered charcoal yeast extract. This process takes 4 to 5 days for detecting the legionella bacteria. The advanced immunological techniques such as polymerase chain reaction and rapid immunological assays are efficient to detect the legionella bacteria in few minutes. These techniques are commonly used to establish the presence of species of Legionella bacteria in the sample. Some of the other drivers for the growth of the global legionella testing market include the entry of new players, new emerging economies such as China and India and increase in the funding for healthcare facilities by the government in many regions. There are about 40 different species of legionella bacteria out of which 18 species are infectious. Among all these species, the legionella pneumophilla bacterium can cause most of the diseases. Many hospitals have started various tests such as legionella urinary antigen test for the initial detection of legionella based diseases. This is the factor expected to further fuel the legionella testing market over the forecast period.

 

The legionella testing market has been divided on the basis of antibiotics used for the treatment of legionella infections into rifampin, azithromycin, ketolides, quinolones and macrolides. It is expected that Azithromycin drug will grow at the fastest rate throughout the forecast period owing to its efficiency to treat legionella based diseases. Azithromycin drug is mainly used for treating this infection in children and adults. The increasing incidences of legionella based diseases in children and adults is also a factor driving the Azithromycin drug segment in the market. Apart, certain flouroquinolones such as moxifloxacin and levofloxacin are also considered as the most efficient drugs for legionella based diseases. There are several diagnostic tests which are available commercially in the market for initial detection of Legionella bacteria in the body such as sputum or lung tissue test, urine antigen test, chest X-ray and blood test. There are various end users of legionella testing drugs which include hospitals, commercial or private labs, physician offices and public health labs.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/legionella-testing-industry

 

Major regions estimated for the legionella testing market are North America, Europe, Asia Pacific and RoW. As of 2013, North America dominated the market attributing the largest share in terms of revenue. This large share can be accounted for by the increasing number of patients suffering from legionella based diseases, the presence of large number of market players and government initiatives such as various public health labs across the region. Owing to the new emerging economies such as Germany and U.K. and rising awareness about legionella based diseases in the Europe region, it is expected that this region will show lucrative growth in the global legionella testing market over the forecast period.

 

The key participants in the legionella testing market include Roche Diagnostics, Beckman Coulter, Bio Rad, Novartis Diagnostics, Life Technology, Becton Dickinson, Abott laboratories, Eiken Chemical, ID Biomedical, Thermo Fischer, Takara Bio, Kreatech, Gen Probe, Enzo Biochem and SeraCare. The market leaders in the global legionella testing market are involved in continuous efforts for the development of innovative methodologies of testing which would increase the efficiency and accuracy of test results while providing the smooth processing of larger samples simultaneously. This companies are also entering into strategic collaborations and expansions to extend their global patient base.

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

Like Reblog Comment
text 2019-03-22 10:52
Ophthalmic Femtosecond Lasers Market Present Chances, Trends, Value Chain And Stakeholder Analysis 2018-2026

Femtosecond laser are ultrafast and ultrashort lasers that release optical pulses 10-15/seconds. The generation of short pulses are achieved by using the passive mode locking technique. This technique is used for generating pulses of light in very short duration (such as for picosecond or femtosecond durations). The femtosecond lasers are popular among ophthalmologists, as such devices help in simplifying and avoiding complex processes of open surgeries. Flap creation in laser in situ keratomileusis (LASIK) is the most common use of this type of laser. It can also be used for other corneal refractive procedures, cataract surgery, and lamellar and full thickness corneal transplantation.

 

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/385

 

The femtosecond laser allows thin and uniform flaps that improve the stability, safety, and precision of the flaps. Added advantage of the femtosecond laser is that it allows the medical doctor to select the cutting angle, position, and diameter of the hinge, as well as the flap diameter and flap thickness, which may offer better flap stability and reduce clinical epithelial ingrowth.

According to Centre for Disease Control and Prevention (CDC), cataract is the prominent blinding condition in the 116 countries enclosed by the Blindness Data Bank in the World Health Organization (WHO) Program for the Prevention of Blindness, nearly 42 million people were affected by severe loss of vision, with cataract being the main cause in 17 million of these cases in 2014. Cataract was the prime cause of blindness in 43.6% of country reports in the same year.

 

Potential target population in the U.S.

According to Centre for Disease Control and Prevention in 2015, approximately 20.5 million people in the U.S. suffered from cataract, mainly those aged 40 years and older. One of the foremost drivers for ophthalmic femtosecond lasers market is an increasing incidence rate of cataract and rising geriatric population. Among emerging economies, cataract is the major cause of severe visual impairment. World Health Organization carried out a population-based prevalence survey for blindness, across various regions in Africa that are not endemic for trachoma or onchocerciasis, and discovered a blindness rate of around 1%, with cataract accounting for 40%-50% of visual loss cases.

 

Refractive error can include near-sightedness (myopia), astigmatism or presbyopia, farsightedness (hyperopia). There are several surgical actions for correcting or adjusting eye's focusing ability by reshaping the cornea, or clear, round dome at the front of your eye. Other procedures involve implanting a lens inside your eye. According to Centres for Disease Control and Prevention (CDC):

 

Factors impeding ophthalmic femtosecond lasers market growth

Major factors which are hindering the growth of this market are shortage of ophthalmologists. Owing to the presence of key players in North America occupied the leading position in this market with largest share. Over the impending years, the strong focus of these players on R & D, the availability of healthcare infrastructure and a well-established regulatory structure for timely approval of the products are likely to support this regional market to retain its position.

 

Due to large base of the population, China is expected to emerge as the most attractive domestic market for ophthalmic lasers in Asia Pacific. The Middle East and Africa and Latin America are also projected to witness a considerable rise in their respective markets for ophthalmic lasers in the near future, due to the thriving medical tourism and the low cost of laser eye surgeries in these regions.

Key players operating in the global ophthalmic femtosecond lasers market are IMRA America, Inc., Newport Corporation, Abbott Medical Optics, Alcon, Bausch & Lomb, Carl Zeiss Meditec, and Ziemer Ophthalmic Systems.

 

Click To Read More On Ophthalmic Femtosecond Lasers Market

Like Reblog Comment
text 2019-03-22 09:24
Osseointegration Implants Market Demands and Gross Margin 2026

The Global Osseointegration Implants Market size was valued at US$ 5,672.3 million in 2017, and is projected to witness a CAGR of 6.72% over the forecast period (2018 – 2026).


Osseointegration is a process in which a bone anchorage is used on an implant surface which provides a basis to support a prosthesis till that part of the body becomes stronger and supports firmly. These implants are used in various applications such as dental implants, bone and joint replacement procedures, and implants undertaken for amputees. The osseointegration implants are made from material such as titanium, zirconia, ceramic, stainless steel, and others.


Increasing demand for osseointegration implants owing to rising number of joint replacement surgeries among geriatric population is expected to drive market growth. According to the Organisation for Economic Cooperation and Development (OECD), on an average, the rate of hip replacement has increased by 30% between 2000 and 2015, and the rate of knee replacement nearly doubled between 2000 and 2015. Moreover, average incidence of the Hip replacement surgery was 166 per 100,000 population in all 34 OECD countries in 2015.


Moreover, key players are opting for different strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE launched a new revolutionary OPRA implant system, which will be initially available only in London and would be distributed through London International Patient Services (LIPS) - an organization seeking treatment for international patients.


Growing Number of Joint Replacement Surgeries Among Geriatric Population is Expected to Drive the Osseointegration Implants Market Revenue


Increasing patient population undergoing joint replacement surgeries has boosted growth of the global osseointegration implants market. According to the National Joint Registry (NJR), in 2017, around 992,090 primary total hip replacements, 1,087,611 knee replacements, 4,687 ankle replacements, 30,720 shoulder replacements, and 2,872 elbow replacements were performed in U.K. Moreover, in U.S, around 17,500 new Spinal Cord Injury (SCI) cases are performed annually and an estimated 285,000 people were suffering from SCI in 2017, as per National Spinal Cord Injury Statistical Center (NSCISC).


Increasing demand for cosmetic dentistry, owing to rising prevalence of dental decays is supporting growth of the global osseointegration implants market. According to the U.S. Department of Health and Human Services, the prevalence of total dental caries among the age group aged 2–19 years was 45.8% and it increases with age, from 21.4% (among age group 2–5) to 50.5% (among age group 6–11) and 53.8% (among age group 12–19) in 2016. Moreover, growing disposable incomes in various countries has also influenced growth of the osseointegration implants market.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2384


Osseointegration Implants Market Restraints


Although demand for osseointegration implants is increasing worldwide, high-cost associated with the implants or surgery with inadequate reimbursement coverage has restrained growth of the osseointegration implants market. In Australia, the surgical procedure to insert the implant is not covered by the Medicare system and is paid through self-funding or by an individual’s Private Health Insurance as per the Australian Orthotic Prosthetic Association. Moreover, risk and complications associated with osseointegration surgery is one of the major factor hampering growth of the market.


Osseointegration Implants Market - Competitive Landscape


Key players operating in the global osseointegration implants market include Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, Southern Implants, ConMed Corporation and others. Manufacturers in osseointegration implants market are focused on expanding their distribution channels in emerging economies, which offers untapped growth opportunities for the growth of the osseointegration implants market.


Osseointegration Implants Market - Regional Insights


On the basis of region, the global osseointegration implants market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold the leading position in the global osseointegration implants market by 2026, owing to well-established healthcare infrastructure, high adoption rate for technologically advanced products, and growing widespread awareness about minimally invasive surgeries. Moreover, high prevalence of degenerative spinal conditions are fueling growth of the market in this region.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

More posts
Your Dashboard view:
Need help?